Zongsheng Guo

PhD
Immunology

Research Interests:

Oncolytic viruses Cancer immunotherapy Small molecules modulating signaling pathways Epigenetic drugs and epigenetic therapy

About Zongsheng Guo

Biography:

I received my PhD in Microbiology and Molecular Genetics from Harvard University in 1990. I conducted my postdoctoral training in gene regulation and later in gene therapy. in 1997, I moved to work in cancer immunotherapy in the Surgery Branch of NCI/NIH, under the leadership of Dr. Steven A. Rosenberg. From 2002-2021, I was a faculty member at University of Pittsburgh School of Medicine, working on the development and applications of oncolytic viruses for cancer immunotherapy. 

In 2021, I came to Roswell Park as Associate Director of VDPF, Translational Immuno-Oncology. In research, I continued to focus on oncolytic viruses and experimental small molecule drugs modulating signaling pathways for cancer immunotherapy.

Positions

Roswell Park Comprehensive Cancer Center
  • Associate Director, Vector Development Production Facility
  • Center for Immunotherapy
  • Department of Immunology

State University of New York at Buffalo

  • Graduate Faculty

Background

Education and Training:

  • 1984-1990 - PhD - Microbiology and Molecular Genetics, Harvard University, Cambridge, MA

Fellowship:

  • 1991-1994 - Associate, Howard Hughes Medical Institute and New York University School of Medicine, New York, NY
  • 1994-1997 - Research Associate, Baylor College of Medicine and Howard Hughes Medical Institute, Houston, TX

Professional Memberships:

  • American Association for Cancer Research
  • American Society of Gene and Cell Therapy
  • Society for Immunotherapy of Cancer

Professional Experience:

  • 2024 - Member, Graduate Faculty in Cancer Science, State University of New York at Buffalo, Buffalo, NY
  • 2021-Present - Associate Director, Vector Development Production Facility, Translational Immuno-Oncology Shared Resource (TIOSR), Roswell Park Comprehensive Cancer Center, Buffalo, NY
  • 2002-2021 - Assistant to Associate Professor, University of Pittsburgh School of Medicine, Pittsburgh, PA

Publications

Full Publications list on PubMed
  • Zhi Z. McGray AJR, Jiang W, Lu B, Kalinski P*, and Guo ZS*. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer 2022; 21:196. [PMID: 36221123]
  • Yang M, Giehl E, Feng C, Feist M, Dai E, Liu Z, Ma C, Ravindranathan R, Bartlett DL, Lu B* and Guo ZS*. IL-36g-armed oncolytic virus exerts superior therapeutic efficacy through induction of potent adaptive antitumor immunity. Cancer Immunol Immunother 2021; 70:2467–2481. [PMID: 33538860]
  • Liu W, Dai E, Liu Z, Ma C, Guo ZS*, and Bartlett DL*. In situ therapeutic cancer vaccination with an oncolytic virus expressing membrane-tethered IL-2. Mol Ther-Oncolytics 2020; 17:350-360. [PMID: 32405533] 
  • Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, Dai E, Roy EJ, Guo ZS*, and Bartlett DL*. Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade. Mol Ther 2018; 26:2476-2486. [PMID: 30064894] 
  • Liu Z, Ravindranathan R, Kalinski P. Guo ZS*, and Bartlett DL*.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 2017; 8:14754. [PMID: 28345650]